Continuous subcutaneous insulin infusion (CSII) has become an indispensable modality in the management of type 1 diabetes. This therapy employs an insulin pump to deliver both basal and bolus ...

The insulin plant is one example of a natural option for controlling blood sugar levels. Few but encouraging small-scale research points to Costus ignis's possible benefits.

In addition, no data are available on the effects of insulin control on preventing dementia in CKD patients with diabetes and hypertension.” Data derived from Chen YY, et al. BMC Nephrol. 2025 ...

Home News Business Stocks Biocon, Wockhardt, Eris to double insulin output, as global drugmakers scale back to focus on GLP-1, new generation insulins ...

The procedure is used exclusively for patients with Type 1 diabetes. It is not considered a treatment for Type 2 diabetes, where insulin resistance is the primary problem ...

Ultrasound can be used to detect early-developing insulin resistance in adults with obesity, according to a study published June 12 in the Journal of Ultrasound Medicine. Here are three things to ...

The beauty of these natural insulin-like foods lies in their accessibility and affordability. Unlike expensive supplements or prescription medications, these five powerful foods are readily ...

The primary endpoint was safety and tolerability and pharmacokinetic data. Secondary endpoints included fasting blood glucose, fasting insulin, lipid levels, and change in body weight at 7 days.

Pharmacokinetic Considerations In humans, inhaled regular insulin is more rapidly absorbed (peak concentrations achieved in 49 65 minutes) than insulin from the subcutaneous injection site (peak ...

SAN DIEGO, June 10, 2025--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced an agreement to develop and commercialize ...

The non-profit drugmaker plans to launch biosimilars of Sanofi’s Lantus (insulin glargine), Novo Nordisk’s Novolog (insulin aspart) and Eli Lilly’s Humalog (insulin lispro) by 2024.

In this paper, a comprehensive pharmacokinetic model for different insulin formulations including insulin Glargine is developed based on the model proposed by Trajanoski et al. (1993). Current models ...